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A lthough lipid deposition in the vessel wall is the hallmark of atherosclerosis, for many years, it has been recognized that inflammation also plays a crucial role in the genesis and progression of the disease and the appearance of clinical manifestations (infarction, stroke). 1 Recently, it has been demonstrated that the modulation of the inflammatory response is a valid target to reduce the risk of atherothrombotic events in high-risk patients. 2 The interplay between lipid metabolism and immune response is not completely understood. In the last decade, the contribution of lymphocytes to atherosclerosis clinical manifestations has been highlighted, and effector T-cell responses seem to be exacerbated in hyperlipidemia. 3, 4 In vivo models of atherosclerosis suggest that regulatory T (Treg) cells suppress inflammatory responses and attenuate atherosclerosis. 5 Experimental therapies aimed to increase Treg cell population under high fat diet (HFD) conditions have conclusively demonstrated an important role for this T-cell subset in atherosclerosis attenuation. 6, 7 The role of Th17 lymphocytes is more controversial. Although genetic or pharmacological inhibition of interleukin (IL)-17 significantly ameliorates atherosclerosis, 8, 9 concomitant increases in both IL-17 and IL-10 lead to smaller plaques. 10 Another study reports bigger plaques in ApoE −/− −/− mice. 11 A Th17/ Treg imbalance has been reported in patients with coronary artery atherosclerosis, with a significant increase in Th17 and a decrease in Treg cells. 12, 13 The early lymphocyte activation antigen CD69 regulates Th17 and Treg cell differentiation. CD69-deficient mice display enhanced Th17 differentiation and defective Treg cell function, [14] [15] [16] resulting in an inability to resolve inflammation or to maintain immune tolerance in diseases such as arthritis, asthma, contact dermatitis, or myocarditis. [17] [18] [19] However, no differences were observed in the atheroma plaque formation in CD69 −/− ApoE −/− mice. 20 A key event in the process of atheroma plaque formation is low-density lipoprotein (LDL) peroxidation, which generates highly inflammatory and immunogenic oxidized LDL (oxLDL). 21 However, oxLDL can also elicit anti-inflammatory responses by activating peroxisome proliferator-activated receptor-γ 22 and liver X receptor or by upregulating transcription factors with anti-inflammatory activity such as NR4A nuclear receptors. 23, 24 The main objectives of this work were to analyze the role of CD69 lymphocyte expression in atherosclerosis development, the immune mechanisms involved, and its relation with human disease. Using chimeric ldlr −/− mice subjected an HFD as atherosclerosis model, we show that CD69 deficiency specifically on lymphocytes leads to an altered Th17/Treg equilibrium and a consequent increase in atheroma plaque size during an HFD. In vitro assays in human T cells showed that the interaction between oxLDL and CD69 activates the expression of NR4A transcription factors, skewing T cells toward a regulatory phenotype and dampening Th17 and Th1 responses. Thus, we describe an unexpected regulatory mechanism of the adaptive immune system that delays atherosclerosis development in hyperlipidemic conditions. Remarkably, our data from participants in the PESA (Progression of Early Subclinical Atherosclerosis) cohort 25 were in agreement with these results in that downregulated CD69 expression in peripheral blood leukocytes (PBLs) is associated with subclinical atherosclerosis in an adjusted multivariable logistic regression model.
METHODS
The data, methods, and study material will be available to other researchers for purposes of reproducing the results or replicating the procedures by contacting the corresponding authors.
Study Design
To analyze the role of CD69 during atherosclerosis development, we used chimeras from ldlr −/− CD45. 
Quantification of CD69 and NR4A Gene Expression in the PESA Study
Expression of CD69 and nuclear receptors NR4A1 was evaluated by reverse transcription PCR with Taqman probes in PBLs of a subset of the participants from the PESA study. 25 This study prospectively enrolled 4184 asymptomatic participants 40 to 54 years of age to evaluate the systemic extent of atherosclerosis in the carotid, abdominal aortic, and iliofemoral territories by 2-dimensional/3-dimensional ultrasound and coronary artery calcification by computed tomography at baseline and 3 and 6 years after enrollment for follow-up studies. Participants were then defined as free of atherosclerosis (no disease; no presence of plaque and a coronary artery calcium score of zero) or with evidence of focal (1 site affected) or generalized (4-6 sites affected) subclinical atherosclerotic disease. 25 Following a general study strategy (ie, not for this specific analysis), 480 individuals of the whole cohort were retrospectively selected on the basis of the extent of subclinical atherosclerosis to perform molecular tests. Individuals were included in this subcohort, prioritizing those with more territories with evidence of plaque at baseline. For those presenting a tie, individuals with coronary artery calcification score ≥1 were included. Control subjects were then selected from those individuals without plaques and matched with the chosen cases on the basis of age, sex, family history of cardiovascular disease, dyslipidemia, and hypertension. From this subpopulation of 480 individuals, we selected 305 male participants classified as without disease (n=122) or with focal (n=55) or generalized (n=128) disease to test the expression of CD69 and NR4A1 by reverse transcription PCR. General characteristics of this specific subcohort are shown in Table I in the onlineonly Data Supplement.
Monitoring Th17 and Treg Cells in the In Vivo Model
To assess the immune response, the percentages of IL-17-eGFP + or Foxp3-RFP + cells in peripheral blood CD4 + T cells were monitored throughout the experiment by flow cytometry. The presence of Th17 and Treg cells was also evaluated at the end point of the experiment in aortic arch, spleen, nondraining (axillary) LNs, and draining (para-aortic) LNs.
OxLDL Binding Assays
Jurkat T (JK) cells or rat basophilic leukemia (RBL) cells stably transfected or not with CD69 were incubated with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-carbocyanine perchlorate-labeled (Dil) LDL in their native and oxidized form in the presence or not of unlabeled lipoproteins. Lipoprotein binding was determined with flow cytometry. In some cases, blocking anti-CD69 antibody was added.
Human CD4 + T Cell Polarization
For human Th1, Th17, and Treg cell polarization, CD4 + T cells were purified from peripheral blood of healthy donors and incubated with a specific cocktail of recombinant cytokines. After the indicated days of culture, cells were analyzed in a FACSCanto Flow Cytometer. When indicated, oxLDL (50 µg/mL) and anti-CD69 (20 µg/mL) were added to the cultures.
Assessment of CD69 and NR4A Transcripts
Expression of mRNA levels of CD69 and NR4A nuclear receptors was analyzed in PBLs from patients with subclinical atherosclerosis and healthy subjects with reverse transcription PCR with Taqman probes (Applied Biosystems). Expression of NR4A receptors was also assessed in Jurkat T cells and human primary lymphocytes in the presence or not of oxLDL. When indicated, blocking anti-CD69 antibodies were also added. NR4A and CD69 mRNA expression was also determined in para-aortic LNs and peripheral blood lymphocytes from mice.
Tissue Processing and Immunohistochemistry
For plaque area assessment, 5-µm-thick sections at 100-µm intervals were collected starting at the origin of the aortic valve cusps. Sections were stained with Oil Red O staining, (Sigma-Aldrich) and hematoxylin, and lesion size was analyzed with ImageJ software. For Masson trichrome staining, 7-µm-thick sections at 100-µm intervals were collected. Sections were stained with the Masson-Goldner staining kit (Merck). For specific staining, anti-F480 antibody was purchased from Abcam (ab6640) and anti-CD3 from Santa Cruz Biotechnology (sc-1127). OxLDL was detected by immunofluorescence with rabbit anti-mouse oxLDL from Abcris.
Statistical Analysis
In vivo experiments were performed according to a randomized complete block design (treatments and different The Cuzick extension of the Wilcoxon rank-sum test was used to assess the significance of the trend in the quantitative PCR data across the 3 ordinal groups allowing for ties. After that, 1-way ANOVA followed by the Tukey posttest was used to identify significant differences between each stage of subclinical atherosclerosis and baseline. Expression levels measured by quantitative PCR were normalized and considered in the log2 scale to fulfill the normality assumption. We then focused on the 2 most extreme groups (no disease versus generalized disease) and used a multivariable logistic regression model to assess the association of CD69 with subclinical atherosclerosis independently of known cardiovascular risk factors (age, smoking, family history of cardiovascular disease, dyslipidemia, hypertension, diabetes mellitus), the expression of NR4A1, oxLDL levels, and volume of different leukocyte subsets. These variables included in the model were found to be statistically significant with a value of P<0.1 in a univariable logistic regression model. Odds ratio, 95% CI, and P value are reported. Traditional cardiovascular risk factors were determined from blood samples and interviews as follows: (1) diabetes mellitus: fasting plasma glucose ≥126 mg/dL or treatment with insulin or oral hypoglycemic medication; (2) arterial hypertension: systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of antihypertensive medication; (3) hypercholesterolemia: total cholesterol ≥240 mg/dL, LDL cholesterol ≥160 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, or use of lipid-lowering drugs; (4) smoking: current smoking status and a lifetime consumption of >100 cigarettes; and (5) family history of cardiovascular disease: first-degree relative diagnosed with atherosclerosis before 55 years of age in men and 65 years of age in women. Linear regression models were used to assess the correlation between the expression levels of CD69 with NR4A1 receptors. All these analyses were implemented with the R statistical software (www.r-project.org).
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RESULTS
Lack of CD69 on Lymphocytes Exacerbates Atherosclerotic Plaque Formation
To evaluate the role of CD69 expression on BM-derived cells in the development of atherosclerosis, male Ldlr ORIGINAL RESEARCH ARTICLE course of HFD in BM Cd69 −/− chimeric mice, whereas the other leukocyte subsets remained unaltered.
To address whether the observed phenotype in BM Cd69 −/− mice is specific to the LC or MC, we generated mixed BM chimeras proficient or deficient for CD69 in either the LC (LC Cd69 +/+ and LC Cd69 −/− groups) or MC ( Figure 1A and Figure III in the online-only Data Supplement). The specific deletion of CD69 on lymphocytes and myeloid cells was confirmed by flow cytometry analysis in the blood of hyperlipidemic mice ( Figure 1A ). We observed a significantly enhanced plateau of Th17 response in the peripheral blood of the LC Cd69 −/− group after HFD, whereas percentages of Foxp3 cells were significantly decreased compared with the Cd69 +/+ group ( Figure 1B and 1C) . On observation that peripheral Th17 responses started to diminish in the LC Cd69 −/− group after week 16 on HFD ( Figure 1C ), mice were euthanized, and immune responses and plaque formation were assessed. IL-17-eGFP + cells in para-aortic LNs from LC Cd69 −/− mice were once again increased, whereas the percentages of Foxp3mRFP + cells were comparable in the 2 groups ( Figure 1D) . However, the absolute number of Treg cells was significant decreased, with a significant increase in the number of Th17 cells (Figure 1D) . Finally, atherosclerotic lesions were significantly more advanced with more extensive necrotic cores in the LC Cd69 −/− group as assessed by Oil Red O and Masson trichrome staining ( Figure 1E and 1F) .
Myeloid cells are pivotal for atherosclerosis development. 28, 29 We next performed mixed BM chimeras proficient or deficient for CD69 in the MC (MC Cd69 We conclude that specific CD69 deletion in the LC accounts for the increased proinflammatory phenotype and the enhanced atheroma plaque formation.
OxLDL Binds to CD69 on T Lymphocytes
The main receptor of oxLDL on vascular cells is lectin-like oxLDL receptor-1 (LOX-1), located in the same chromosomal locus immediately upstream to CD69. The LOX-1 and CD69 C-type lectin-like domains form very similar dimers (Figure 2A, left) , unlike other C-type lectins such as dectin-1 or the macrophage mannose receptor (Figure V in the online-only Data Supplement). In LOX-1, the oxLDL-binding surface is located at the top of the dimer and contains a unique basic "spine" formed by the diagonal arrangement of arginine residues across the dimer surface (Figure 2A, top right) . 30, 31 Electrostatic surface representation of the CD69 C-type lectin-like domain dimer indicated that 4 arginine residues cluster at the center of the dimer and form a basic spine, similar to that of LOX-1 (Figure 2A, bottom right) . Because this structural feature is proposed to be important for oxLDL recognition, 30 we hypothesized that CD69 binding to oxLDL particles could account for the phenotype observed in vivo.
Transfected Jurkat T cells stably expressing CD69 (JKCD69) on their surface bound oxLDL-DiI much more efficiently than untransfected JK (JKwt) cells ( Figure 2B and 2C). JKCD69 cells bound oxLDL in a dose-dependent manner and showed a weaker binding of native LDL ( Figure 2D ). This binding was able to induce CD69 internalization in JKCD69 cells ( Figure 2E ). The specificity of oxLDL binding to CD69 was confirmed in blocking assays with anti-CD69 antibodies ( Figure 2F ).
CD69/oxLDL Binding Controls Th17/Treg Equilibrium and Expression of NR4A Nuclear Receptors
OxLDL exposure significantly reduced the mRNA levels of IL-8 and interferon-γ (IFN-γ) produced by JKCD69 cells but not in JKwt cells after activation ( Figure 3A) . Because of the role of CD69 in effector T-cell differentiation, 16 we evaluated human T-cell differentiation to effector phenotypes. Challenge of human CD4 + T cells with oxLDL diminished the percentage of IL-17 + and IFN-γ + cells generated in response to Th17-or Th1-polarizing stimuli ( Figure 3B and 3C) and favored Treg differentiation ( Figure 3D ). This effect was dependent on CD69, as demonstrated by the blockade with anti-CD69 antibodies ( Figure 3B through 3D) .
The NR4A orphan nuclear receptors have emerged as key regulators of the immune response, controlling the magnitude of the inflammatory processes; NR4A1 and NR4A3 are crucial for Treg cell development. 23, 24 We assessed whether oxLDL regulates the expression of NR4A nuclear receptors (NR4A1 and NR4A3) in human CD4 + T cells. As shown in Figure 3E , oxLDL enhanced NR4A1 and NR4A3 mRNA expression in T-cell receptoractivated human primary CD4 + T cells. An early induction of NR4A3 was also evoked by oxLDL in JKCD69 cells but not in JKwt cells (Figure 3F ), which was blocked by preincubation with anti-CD69 antibodies ( Figure 3G ) or shRNA, confirming the CD69-dependent effect of oxLDL ( Figure 3H ). 
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In the in vivo model of atherosclerosis, the reporter GFP + Th17 cells and oxLDL localized closely at the atheroma plaque. Moreover, CD3 + T cells and oxLDL colocalized at atheroma plaque ( Figure VIA and VIB in the online-only Data Supplement). NR4A1 and NR4A3 mRNA expression was decreased in para-aortic LNs from BM Cd69 −/− mice after 13 weeks of HFD ( Figure 3I ). Moreover, PBL expression of CD69 and NR4A1 transcripts gradually declined in ldlr −/− mice during HFD administration ( Figure 3J ), indicating that these receptors are dynamically regulated in PBLs under these conditions.
CD69 Expression Is an Early Predictor of Subclinical Atherosclerosis
The PESA study is a prospective study that uses advanced imaging techniques to assess the presence of atheroma plaque in the main arteries of healthy individuals. Having observed a significant downregulation of CD69 as plaque formation progressed in mice, we compared CD69 and NR4A1 mRNA expression in PBLs from PESA participants with focal (1 affected site, n=55) or generalized (4-6 affected sites, n=128) subclinical atherosclerosis with that of PESA participants without any evidence of subclinical atherosclerosis (n=122; Table  I in the online-only Data Supplement). The extent of subclinical atherosclerosis was assessed with advanced imaging techniques. 25 There is a gradient in CD69 expression across atherosclerosis extension stages; that is, CD69 expression decreases as disease progresses (trend test, P=0.006; Figure 4A ). The same is true for NR4A1 (trend test, P=0.003; Figure 4A ). These differences were particularly significant for the generalized subclinical disease group (Figure 4B and 4C) . Thus, we focused on ORIGINAL RESEARCH ARTICLE the control group (no disease) versus generalized disease group and examined whether CD69 can be used as independent marker for subclinical atherosclerosis. After a univariable logistic regression analysis (Table II in the online-only Data Supplement) of relevant variables (known cardiovascular risk factors: age, smoking, BMI, hypercholesterolemia, hypertension, diabetes mellitus, family history of cardiovascular disease; peripheral count of different subsets of leucocytes; expression of NR4A1 and the levels of oxLDL and C-reactive protein), a multivariable logistic regression analysis determined that CD69 expression remained an independent predictor of atherosclerosis at an early stage (odds ratio, 0.62; P=0.0056; Table) . Furthermore, CD69 levels correlated significantly with NR4A1 levels ( Figure 4D and Table III in the online-only Data Supplement), supporting the notion of a common regulation pathway.
DISCUSSION
Our findings indicate that the absence of CD69 in the LC results in larger atheroma plaque formation in ldlr −/− deficient mice subjected to an HFD. We identify the functional interaction between CD69 and oxLDL as the mechanism responsible for the observed phenotype. Our clinical data support this concept because CD69 expression in peripheral leucocytes of subjects with subclinical atherosclerosis is downregulated compared with individuals without atherosclerosis. This finding was in agreement with the experimental evidence showing a downregulation of CD69 expression on T lymphocytes in mice on exposure to HFD. Despite a suggested role for oxLDL in adaptive immune responses, a putative receptor on T lymphocytes has remained elusive. 32 Our study demonstrates that binding of oxLDL to CD69 in human T cells has a protective effect against the inflammatory response through the expression of NR4A nuclear receptors, downregulating proinflammatory cytokines and promoting Treg differentiation.
Although the classic view is that oxLDL induces the recruitment of inflammatory cells to the subendothelial space, cells and tissues also respond to oxLDL through the inhibition of proinflammatory signaling pathways. 33, 34 The NR4A subfamily of human nuclear receptors (NR4A1 [Nur77], NR4A2 [Nurr1] and NR4A3 [NOR-1]) can be induced in endothelial and smooth muscle cells by a range of stimuli (including oxLDL), regulating the expression of different molecules involved in the immune response.
35 NR4A overexpression decreases the levels of IL-1β, IL-8, and monocyte chemoattractant protein-1 inflammatory cytokines. Furthermore, NR4A1 and NR4A3 have been implicated in Treg differentiation. 23, 24 Our data show that binding of oxLDL to CD69 in human T cells induces the expression of NR4A receptors. Moreover, the absence of CD69 during atherosclerosis development results in a lower expression of NR4A1 and NR4A3 in both PBLs and para-aortic LNs. The observation of the regulatory effect of CD69/oxLDL interaction in human Treg differentiation, together with the loss of Treg responses observed in lymphocyte CD69-deficient mice during atherosclerosis development, suggests that the modulation of NR4A nuclear receptors could participate in CD69 signaling/Treg differentiation. The more extensive atherosclerosis developed in the absence of CD69 could be associated, at least in part, with defects in Treg cell differentiation. Treg cells exert an atheroprotective function through the suppression of T-cell proliferation and secretion of anti-inflammatory cytokines and are protective during the initial phases of atherosclerosis not only by reducing atherosclerotic plaque formation but also by improving stabilization of the atherosclerotic lesions. [36] [37] [38] Besides promoting Treg cell function, CD69 controls Th17 differentiation through the association of its cytoplasmic tail with the Jak3/Stat5 signaling pathway, regulating RAR-related orphan receptor-γ transcription and differentiation toward the Th17 lineage. 15 Recent evidence for the role of IL-17 in atherosclerosis has shed little light on the subject in both proatherogenic and antiatherogenic roles. 39, 40 Under HFD, ldlr −/− mice deficient for CD69 in the LC developed exacerbated Th17 responses and more severe atherosclerotic lesions, supporting the role of IL-17 as a proatherogenic molecule. Despite previous reports supporting that IL-17 can either stabilize the plaque through collagen production or enhance the recruitment of proatherogenic cells through CXCL1 upregulation, 11,40 the former seems not to be the case in our model. Increased amounts of IL-17 seem to stabilize plaque formation when levels of IL-10 are also higher, namely in the presence of a proper 41, 42 This is a very important issue to be considered that could account for the differences observed between CD69
−/− /apoE −/− and CD69 −/− /Ldlr −/− models. Our data show that oxLDL binding to CD69 exerts an immune-regulatory function during atherosclerosis development. In the ApoE knockout model, the levels of LDL may not have reached the threshold that is required for signaling through CD69. An additional difference that should be taken into consideration is that Ldlr −/− lesions have higher T-cell density than the ApoE model, 43 meaning that Ldlr −/− mice have more T cells that could express CD69 to exert their function. Finally, ApoE −/− mice on an HFD develop plaques more rapidly and exhibit larger aortic lesions with larger necrotic cores than Ldldr −/− mice 41, 42 ; therefore, this high-intensity model could be masking the differences between the CD69-expressing and CD69-deficient animals. We found a significant decrease in the blood lipid profile of free fatty acids, triglycerides, high-density lipoprotein, LDL, and cholesterol in the Cd69 −/− lymphoid chimeras. This "dissociation" of the immune profile of the organism from the metabolic parameters is quite intriguing; it seems to occur via mechanisms related mainly to the adaptive immune responses (in this case, lack of CD69 and Th17 propensity). Our data pave the way for further research on mechanisms that could contribute to atherogenesis.
Our results describe for the first time an oxLDL receptor on lymphocytes with an important function in the regulation of the adaptive immune response and atheroma plaque formation during an HFD. The chimeric ldlr −/− mouse models used shed light on the role of CD69/oxLDL functional interaction in lymphocytes and on the maintenance of immune homeostasis to protect medium and large arteries from severe atheroma plaque formation over time. Further studies of the new regulatory oxLDL/CD69 pair in human lymphoid cells during atherosclerotic disease progression will provide novel insight into targeting these pathways for the prognosis/treatment of cardiovascular diseases.
Recent data emphasized the link between the inflammatory response and atherosclerotic risk in the clinical arena. 2 However, the complex interplay between lipid metabolism and immune responses remains to be fully disclosed. Collectively, our in vivo data strongly indicate an important role for CD69 expression on lymphocytes during atherosclerosis development. To validate this new paradigm in humans, we assessed the expression of CD69 and NR4A in PBLs from a cohort of subjects with thoroughly characterized subclinical atherosclerosis. It is important to point out that all PESA participants included in the study were asymptomatic and free of events. The profile of CD69 expression detected in human samples was very similar to that observed in the in vivo model. If we consider focal disease and generalized disease as different stages with the same pathology, our data indicate that expression of CD69 gradually declines as disease progresses. Hence, we focused on the generalized disease group, which is still preclinical, to assess the association of the expression of CD69 with subclinical atherosclerosis, accounting for the effect of traditional risk factors, peripheral counts of different subsets of leucocytes, expression of NR4A1, and levels of oxLDL. The proof of clinical study more closely resembling the animal experiments was to compare subjects free of disease or no disease versus those with established but yet subclinical atherosclerosis or generalized subclinical disease. CD69 remained significantly associated with the extent of the disease after adjustment for risk factors. This finding underscores the putative role of CD69 as a potential marker for the detection of atherosclerosis at a preclinical stage.
The fact that atherosclerosis presence is well identified in a context different from acute conditions (eg, myocardial infarction) supports the causative role of CD69 expression on atherosclerosis development rather than a consequence of an acute event. 
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